A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.

Hiroki Saito, Satoshi Ando, Naoya Morishita, Kyung-Mi Lee, Dante Dator, David Dy, Katsumi Shigemura, Zainal Adhim, Ken Ichi Nibu, Masato Fujisawa, Toshiro Shirakawa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer. Copyright

Original languageEnglish
Pages (from-to)3365-3370
Number of pages6
JournalAnticancer Research
Volume34
Issue number7
Publication statusPublished - 2014 Jan 1

Fingerprint

Lymphokine-Activated Killer Cells
Gene therapy
Lymphokines
p53 Genes
Adenoviridae
Genetic Therapy
Immunotherapy
Tumor Necrosis Factor-alpha
Cytotoxicity
Messenger RNA
Head and Neck Neoplasms
Reverse Transcription
Carrier Proteins
Polymerase chain reaction
Transcription
Carcinoma, squamous cell of head and neck
Epithelial Cells
Ligands
Polymerase Chain Reaction
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. / Saito, Hiroki; Ando, Satoshi; Morishita, Naoya; Lee, Kyung-Mi; Dator, Dante; Dy, David; Shigemura, Katsumi; Adhim, Zainal; Nibu, Ken Ichi; Fujisawa, Masato; Shirakawa, Toshiro.

In: Anticancer Research, Vol. 34, No. 7, 01.01.2014, p. 3365-3370.

Research output: Contribution to journalArticle

Saito, H, Ando, S, Morishita, N, Lee, K-M, Dator, D, Dy, D, Shigemura, K, Adhim, Z, Nibu, KI, Fujisawa, M & Shirakawa, T 2014, 'A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.', Anticancer Research, vol. 34, no. 7, pp. 3365-3370.
Saito, Hiroki ; Ando, Satoshi ; Morishita, Naoya ; Lee, Kyung-Mi ; Dator, Dante ; Dy, David ; Shigemura, Katsumi ; Adhim, Zainal ; Nibu, Ken Ichi ; Fujisawa, Masato ; Shirakawa, Toshiro. / A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. In: Anticancer Research. 2014 ; Vol. 34, No. 7. pp. 3365-3370.
@article{f535580cabf040ab9e767a58067af614,
title = "A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.",
abstract = "The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer. Copyright",
author = "Hiroki Saito and Satoshi Ando and Naoya Morishita and Kyung-Mi Lee and Dante Dator and David Dy and Katsumi Shigemura and Zainal Adhim and Nibu, {Ken Ichi} and Masato Fujisawa and Toshiro Shirakawa",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "3365--3370",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "7",

}

TY - JOUR

T1 - A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.

AU - Saito, Hiroki

AU - Ando, Satoshi

AU - Morishita, Naoya

AU - Lee, Kyung-Mi

AU - Dator, Dante

AU - Dy, David

AU - Shigemura, Katsumi

AU - Adhim, Zainal

AU - Nibu, Ken Ichi

AU - Fujisawa, Masato

AU - Shirakawa, Toshiro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer. Copyright

AB - The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer. Copyright

UR - http://www.scopus.com/inward/record.url?scp=84906343606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906343606&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 3365

EP - 3370

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 7

ER -